Onsdag 2 September | 14:03:56 Europe / Stockholm
Est. tid*
2027-02-09 07:00 Bokslutskommuniké 2026
2026-11-03 07:00 Kvartalsrapport 2026-Q3
2026-08-18 - Kvartalsrapport 2026-Q2
2026-06-10 - X-dag ordinarie utdelning OSSD 0.00 SEK
2026-06-09 - Årsstämma
2026-05-05 - Kvartalsrapport 2026-Q1
2026-02-03 - Bokslutskommuniké 2025
2025-11-04 - Kvartalsrapport 2025-Q3
2025-08-19 - Kvartalsrapport 2025-Q2
2025-06-12 - X-dag ordinarie utdelning OSSD 0.00 SEK
2025-06-11 - Årsstämma
2025-05-06 - Kvartalsrapport 2025-Q1
2025-02-04 - Bokslutskommuniké 2024
2024-12-18 - Extra Bolagsstämma 2024
2024-11-12 - Kvartalsrapport 2024-Q3
2024-08-20 - Kvartalsrapport 2024-Q2
2024-05-22 - X-dag ordinarie utdelning OSSD 0.00 SEK
2024-05-21 - Årsstämma
2024-05-14 - Kvartalsrapport 2024-Q1
2024-02-06 - Bokslutskommuniké 2023
2023-11-21 - Kvartalsrapport 2023-Q3
2023-10-16 - Extra Bolagsstämma 2023
2023-08-22 - Kvartalsrapport 2023-Q2
2023-06-01 - X-dag ordinarie utdelning OSSD 0.00 SEK
2023-05-31 - Årsstämma
2023-05-23 - Kvartalsrapport 2023-Q1
2023-02-21 - Bokslutskommuniké 2022
2022-11-22 - Kvartalsrapport 2022-Q3
2022-08-23 - Kvartalsrapport 2022-Q2
2022-06-03 - X-dag ordinarie utdelning OSSD 0.00 SEK
2022-06-02 - Årsstämma
2022-05-24 - Kvartalsrapport 2022-Q1
2022-02-22 - Bokslutskommuniké 2021
2021-11-17 - Kvartalsrapport 2021-Q3
2021-08-18 - Kvartalsrapport 2021-Q2
2021-05-20 - X-dag ordinarie utdelning OSSD 0.00 SEK
2021-05-19 - Årsstämma
2021-05-12 - Kvartalsrapport 2021-Q1
2021-04-09 - Extra Bolagsstämma 2021
2021-02-11 - Bokslutskommuniké 2020
2020-11-11 - Kvartalsrapport 2020-Q3
2020-08-19 - Kvartalsrapport 2020-Q2
2020-05-22 - X-dag ordinarie utdelning OSSD 0.00 SEK
2020-05-20 - Årsstämma
2020-05-13 - Kvartalsrapport 2020-Q1
2020-02-13 - Bokslutskommuniké 2019
2019-11-19 - Kvartalsrapport 2019-Q3
2019-08-21 - Kvartalsrapport 2019-Q2
LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
OssDsign är en utvecklare och leverantör av ortobiologiska produkter. Bolaget utvecklar och marknadsför produkter som stödjer kroppens egen läkningsförmåga, exempelvis OssDsign Catalyst, som är ett nanosyntetiskt bentransplantat för dubbla benbildningsvägar genom fusionsmassa. Bolaget erbjuder sina produkter runtom den globala marknaden. OssDsign grundades 2011 och har sitt huvudkontor i Uppsala.

Analysera bolaget i Börsdata!

All ägardata du vill ha finns i Holdings!

OssDsign AB (publ) publishes Q2 2026 interim report

2026-08-18 07:00:00

Progress: Building the foundation for OssDsign growth

OssDsign AB (publ) announces that the interim report for Q2 2026 is now available as a PDF on the company's website www.ossdsign.com/reports. A PDF version is also attached to this press release.

 

The Q2 2026 results will also be presented at an investor webcast today August 18th at 11:00 CEST. The webcast can be accessed via the following link: https://access.dnbcarnegie.com/companies/1392/live or via the OssDsign website.  

 

 

The second quarter in figures

  • Net sales amounted to TSEK 37,776 (46,522), which translates to a flat growth quarter-over-quarter with constant exchange rates, or 2.4% growth in reported figures. This is in line with expectations and our market guidance.
  • Gross margin of 92.1% is an improvement over the 91.6% in the first quarter of 2026 but below the 96.8% in the second quarter of the previous year, negatively affected by product and customer mix.
  • Reported EBIT of TSEK -12,348 (-6,936).
  • Adjusted EBIT of TSEK -11,975 (-6,203), with the reduction in sales variable costs making up for some of the gross profit shortfall.
  • Operating expenses were lower than last year with non-sales variable costs being level with last year. Sales variable costs were down to 44.8% (48.6%) of net sales in the period.
  • Net result for the period amounted to TSEK -11,408 (-8,340).
  • Earnings per share of SEK -0.1 (-0.1).
  • Cash flow from operating activities of TSEK -11,811 (-11,895), level with last year due to the positive working capital development.

 

The first half year in figures

  • Net sales amounted to TSEK 74,655 (91,016), which translates to a decrease of 10% with constant exchange rates, or 18% in reported figures. The significant divergence in growth rates is entirely attributable to the exchange rate depreciation of the USD relative to the SEK, from 10.2 to 9.2, during the comparison periods.
  • Gross margin of 91.9% (96.6%). The margin was negatively affected by product and customer mix.
  • Reported EBIT of TSEK -25,813 (-19,633).
  • Adjusted EBIT of TSEK -25,363 (-11,766), as a direct consequence of the lower sales and gross margin, with some mitigation from lower operating expenses.
  • Operating expenses were lower than last year and sales commissions and fees were down to to 45.9% (49.0%) of net sales in the period.
  • Net result for the period amounted to TSEK -22,882 (-22,917).
  • Earnings per share of SEK -0.2 (-0.2).
  • Cash flow from operating activities of TSEK -26,677 (-37,769), primarily due to the favourable working capital development in the first half of 2026.

 

Significant events during the second quarter

  • OssDsign Catalyst® outperforms earlier-generation bone graft as a standalone treatment in trauma study.
  • OssDsign appoints Adam McCollister as new Vice President
    of Sales.

 

Significant events after the end of the second quarter

  • There were no significant events after the end of the second quarter.